AML-348 A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated hematologic malignancies by Lachowiez, C, Borthakur, G, Loghavi, S, Zeng, Z, Kadia, T, Masarova, L, Takahashi, K, Tippett, G, Garcia, J, Bose, P, Jabbour, E, Ravandi, F, Daver, N, Manero, GG, Vyas, P, Kantarjian, H, Konopleva, M, DiNardo, C